Trial EVIDENT

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

EVIDENT

Full title

An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors

Responsible organization

k.A.

Classification	Code	Description
-	-	Other trials

Phase

III

Status

Recruitment finished

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

' - Therapieart:

	Function	Prename	Surname	Organization
	Responsible contact	Bruno	Neu	k.A.